VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Patients enrolled to the study had chronic lymphocytic leukemia (CLL) and received ibrutinib. Patients had either received ibrutinib for one year without having had a complete response or patients developed a resistance mutation to ibrutinib. This study had two parts, a dose escalation part and a dose expansion part.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03400176.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationNovartis Pharmaceuticals Corporation

• Primary IDCVAY736Y2102
• Secondary IDsNCI-2018-00563, 5R01CA177292-09
• ClinicalTrials.gov IDNCT03400176